Akers Biosciences Inc.
| NASDAQ: AKER | Healthcare / Medical Devices & Instruments / USA |
| 2.47 | -0.2600 | -9.52% | Vol 1.58M | 1Y Perf -32.69% |
| Apr 16th, 2021 16:00 DELAYED |
| BID | 2.40 | ASK | 2.53 | ||
| Open | 2.65 | Previous Close | 2.73 | ||
| Pre-Market | - | After-Market | 2.43 | ||
| - - | -0.04 -1.62% |
| Target Price | - | Analyst Rating | — 0.00 | |
| Potential % | - | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★★★★ 66.01 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Market Cap | 41.13M | Earnings Rating | Buy | |
| Price Range Ratio 52W % | 15.41 | Earnings Date | 21st May 2021 |
Today's Price Range 2.403.04 | 52W Range 1.656.97 | 5 Year PE Ratio Range -0.6000-1.20 |
Summary:
Sell
| Technical Indicators: | Sell |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -23.05% | ||
| 1 Month | -32.88% | ||
| 3 Months | -6.79% | ||
| 6 Months | 8.81% | ||
| 1 Year | -32.69% | ||
| 3 Years | -97.60% | ||
| 5 Years | -99.23% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -94.75 | |||
ROE last 12 Months | -78.80 | |||
ROA (5Y Avg) | -36.70 | |||
ROA last 12 Months | -72.21 | |||
ROC (5Y Avg) | -95.03 | |||
ROC last 12 Months | -127.53 | |||
Return on invested Capital Q | -11.92 | |||
Return on invested Capital Y | -80.84 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | -0.70 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.20 | ||||
| 1.61 | ||||
| -159.88 | ||||
| - | ||||
| -5.60 | ||||
| -1.69 | ||||
| 1.61 | ||||
| 2.07 | ||||
| 20.10M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 16.10 | ||||
| 16.30 | ||||
| 0.02 | ||||
| 0.00 | ||||
| - | ||||
| Leverage Ratio | 1.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 30.40 | ||||
| -649.20 | ||||
| -646.20 | ||||
| -280.80 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -363 515.00 | ||||
| -0.02 | ||||
| -49.94 | ||||
| -29.21 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2020 | - | -0.38 | - |
| Q01 2020 | - | -1.59 | - |
| Q03 2019 | - | -0.07 | - |
| Q02 2019 | - | -0.06 | - |
| Q01 2019 | - | -0.07 | - |
| Q04 2018 | - | -0.34 | - |
| Q03 2018 | - | -0.26 | - |
| Q02 2018 | - | -0.02 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 21st May 2021 |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 1.58M |
| Shares Outstanding | 16.65M |
| Trades Count | 7.89K |
| Dollar Volume | 1.18M |
| Avg. Volume | 770.29K |
| Avg. Weekly Volume | 697.67K |
| Avg. Monthly Volume | 347.60K |
| Avg. Quarterly Volume | 810.80K |
Akers Biosciences Inc. (NASDAQ: AKER) stock closed at 2.47 per share at the end of the most recent trading day (a -9.52% change compared to the prior day closing price) with a volume of 1.58M shares and market capitalization of 41.13M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 12 people. Akers Biosciences Inc. CEO is Christopher Charles Schreiber.
The one-year performance of Akers Biosciences Inc. stock is -32.69%, while year-to-date (YTD) performance is 24.12%. AKER stock has a five-year performance of -99.23%. Its 52-week range is between 1.65 and 6.97, which gives AKER stock a 52-week price range ratio of 15.41%
Akers Biosciences Inc. currently has a PE ratio of -1.20, a price-to-book (PB) ratio of 1.61, a price-to-sale (PS) ratio of -159.88, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -72.21%, a ROC of -127.53% and a ROE of -78.80%. The company’s profit margin is -%, its EBITDA margin is -646.20%, and its revenue ttm is $-363 515.00 , which makes it $-0.02 revenue per share.
Of the last four earnings reports from Akers Biosciences Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Akers Biosciences Inc.’s next earnings report date is 21st May 2021.
The consensus rating of Wall Street analysts for Akers Biosciences Inc. is — (0), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Akers Biosciences Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Akers Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Akers Biosciences Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 22.48, ATR14 : 0.44, CCI20 : -197.90, Chaikin Money Flow : -0.46, MACD : -0.11, Money Flow Index : 28.18, ROC : -19.28, RSI : 40.56, STOCH (14,3) : 5.83, STOCH RSI : 0.00, UO : 31.81, Williams %R : -94.17), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Akers Biosciences Inc. in the last 12-months were:
Akers Biosciences Inc.
Akers Biosciences Inc is engaged in developing, manufacturing and supplying rapid, point-of-care screening and testing products designed to bring health-related information directly to the patient or clinician in a time- and cost-efficient manner. The pipeline products of the company focus on delivering diagnostic assistance in a variety of healthcare fields/specialties, including cardiology/emergency medicine, metabolism/nutrition, diabetes, respiratory diseases and infectious disease detection. The majority of the company's revenue comes from the United States.
CEO: Christopher Charles Schreiber
Telephone: +1 856 848-8698
Address: 201 Grove Road, Thorofare 08086, NJ, US
Number of employees: 12
